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Abstract
Previous studies have demonstrated that the behavioral effects of nicotine withdrawal are
lower in adolescent versus adult rats. However, the neurochemical mechanisms that mediate
these developmental differences are presently unclear. Much work has shown that nicotine
reward is mediated via enhanced dopamine neurotransmission in the mesolimbic pathway which
originates in the ventral tegmental area (VTA) and terminates in several forebrain structures
including the nucleus accumbens (NAcc). More recently, studies have shown that nicotine
withdrawal produces a decrease in NAcc dopamine transmission, an effect that is believed to
serve as a neurochemical marker of withdrawal in adult rodents. The goal of this project was to
understand whether developmental sensitivity to nicotine withdrawal is mediated via
dopaminergic mechanisms in adolescent versus adult rats. Thus, extracellular levels of dopamine
in the NAcc were compared in adolescent and adult rats experiencing nicotine withdrawal.
Following 13 days of nicotine exposure, the rats were implanted unilaterally with microdialysis
probes into the NAcc and the ipsilateral VTA. The next day, dialysate samples were collected
following administration of the nicotinic-receptor antagonist mecamylamine to precipitate
withdrawal. The physical signs of withdrawal were also examined in the same animals during
baseline and then following systemic mecamylamine administration. The results revealed that
mecamylamine precipitated the physical signs of withdrawal in both age groups; however, the
total number of physical signs was larger in nicotine-dependent adult versus adolescent rats. The
microdialysis results revealed that mecamylamine produced a decrease in extracellular levels of
dopamine in the NAcc that was larger in adults (44% decrease) versus adolescents (20%). A
similar pattern of developmental differences was observed with the dopaminergic metabolites
(3,4-dihydroxyphenlyacetic acid and homovanillic acid). However, an assessment of the
serotonergic metabolite (5-hydroxyindoleacetic acid) revealed that there were no developmental
v

differences in this measure during nicotine withdrawal. A follow-up study compared
extracellular levels of NAcc dopamine in adolescent and adult rats receiving intra-VTA
administration of bicuculline, which reduces gamma-aminobutyric acid (GABA) inhibition of
dopamine neurotransmission. The results revealed that blockade of GABA receptors in the VTA
produced a 2-fold increase in NAcc dopamine of adult, but not adolescent rats. The results of
these studies provide a potential mechanism involving dopamine that mediates developmental
differences in nicotine withdrawal. Specifically, they suggest that GABAergic systems are
underdeveloped during adolescence, and this reduced inhibition of dopamine neurons in the
VTA may lead to reduced decreases in NAcc dopamine of adolescent versus adult rats during
nicotine withdrawal.
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Introduction
Adolescent tobacco use is a major health and economic concern: It is currently estimated
that 21% of high school students in the USA are cigarette smokers (Centers for Disease Control;
CDC, 2008). This trend of adolescent tobacco use is alarming in light of growing evidence that
adolescents are particularly vulnerable to tobacco addiction. For example, clinical studies have
found that people who begin smoking as adolescents are more likely to become heavy smokers
later in life (Rigotti et al., 1990; Riala et al., 2004; Glynn et al., 1993). This is a major health
concern since the development of many diseases such as lung cancer, coronary heart disease, and
stroke are highly correlated with long-term tobacco use (U.S. Department of Health and Human
Services, 2004). Moreover, the increasing rate of nicotine dependence and smoking-related
diseases produce economic consequences such as rising healthcare costs and losses in worker
productivity (CDC, 2005). Despite severe health and economic concerns regarding tobacco use
during adolescence, the mechanisms that motivate tobacco abuse in this age group are not well
understood.
Adolescent smokers display reduced withdrawal symptoms during abstinence: It is well
established that nicotine withdrawal plays a major role in motivating continued use of tobacco
products and in driving relapse during abstinence in adult tobacco users (Benowitz, 2008;
Buchhalter et al., 2008; Carmody et al., 2007). However, to our knowledge, no one has directly
compared the intensity of withdrawal symptoms in adolescent versus adult tobacco users. Thus,
the contribution of nicotine withdrawal to adolescent tobacco abuse is unclear. Recent clinical
reports suggest anecdotally that nicotine withdrawal symptoms are milder in adolescents versus
adults, and that the negative effects of withdrawal do not appear to be related to relapse behavior
in adolescent smokers (Smith et al., 2008a; Smith et al., 2008b). Moreover, clinical studies have

1

reported that treatment strategies that focus on alleviating the negative effects of nicotine
withdrawal, such as the nicotine patch, do not improve abstinence rates in adolescent smokers
(Hanson et al., 2003; Moolchan et al., 2005). One possible explanation for these findings is that
adolescents do not experience the negative effects of withdrawal during abstinence from
nicotine, and as a result, treatments that target withdrawal may not be expected to reduce tobacco
abuse in this young age group. These differences in withdrawal symptoms and treatment
outcomes suggest that the mechanisms that mediate nicotine withdrawal are different in
adolescents as compared to adults.
Animal models of adolescence in rats: Animal models involving rodent preparations have
been widely used to study developmental differences in the physiological mechanisms that
mediate the behavioral effects of nicotine. Researchers studying developmental differences in
rats have been challenged with determining the exact boundaries of the adolescent period.
However, most researchers agree that the period of adolescence conservatively ranges from PND
28-42 (Spear, 2000). Although it is difficult to define an exact time frame of adolescence, most
researchers agree that this phase of development is a period of transition that encompasses a
series of events with no single event that signals an onset or termination, such as puberty that is
signaled by sexual maturation. Adolescence reflects a period during which age-specific
behavioral discontinuities from younger and older animals are most evident. In rats, most
behavioral and physiological systems reach maximal maturation by PND 60, and are considered
adults beyond this age. The present study tested adolescent rats between 41-43 days of age and
adult rats beyond 60 days of age.
Studying nicotine withdrawal in rats: Nicotine withdrawal has been widely studied in
adult rats that receive chronic administration of nicotine via subcutaneous osmotic pumps
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(Kenny and Markou, 2001; Malin, 2001; O’Dell et al., 2006). Following nicotine exposure for at
least 5-7 days, nicotine withdrawal is induced either by surgically removing the nicotine pump
(i.e., spontaneous withdrawal) or by administering a nicotinic acetylcholine receptor antagonist
such as mecamylamine to pharmacologically induce withdrawal (i.e., precipitated withdrawal).
Much work has shown that nicotine withdrawal, under both spontaneous and precipitated
withdrawal conditions, produces an increase in negative affective states such as anxiety-like
behavior and aversion for environmental cues that are repeatedly paired with nicotine withdrawal
(O’Dell and Khroyan, 2009). Also, spontaneous and precipitated nicotine withdrawal produce an
increase in physical somatic signs, including eye blinks, writhes, body shakes, teeth chatters,
gasps, and ptosis. Studies examining the physical signs of nicotine withdrawal commonly report
the total number of all of these signs because it is difficult to detect group differences with an
analysis of any individual sign that occurs in low frequency. However, we have reported that
group differences with total signs are consistent with an individual analysis of eye blinking
(O’Dell et al., 2004).
Nicotine withdrawal is lower in adolescent versus adult rats: Rodent studies examining
developmental differences in nicotine withdrawal have shown that both the physical and negative
affective properties of nicotine withdrawal are lower in adolescent relative to adult rats. For
example, work in our laboratory has demonstrated that adolescent rats display fewer physical
signs of withdrawal relative to adults across a range of nicotine doses to produce dependence and
across a range of mecamylamine doses to precipitate withdrawal (O’Dell et al., 2004, 2006).
Subsequent behavioral studies in our laboratory demonstrated that adolescents also display a
reduced place aversion to an environment paired previously with nicotine withdrawal relative to
adults (O’Dell et al., 2007). Moreover, work in other laboratories has established that the
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behavioral effects of nicotine withdrawal are lower in adolescent rats and mice relative to their
adult counterparts. For example, Kota et al. (2007) demonstrated that nicotine-dependent
adolescent mice display fewer signs of nicotine withdrawal under both spontaneous and
precipitated conditions relative to adults. Shram et al. (2008) also demonstrated that adolescent
rats given a range of nicotine doses to produce dependence display a lack of place aversion and
physical signs of withdrawal relative to adults under spontaneous and precipitated withdrawal
conditions. Collectively, these behavioral studies suggest that adolescence is a period of
development characterized by reduced sensitivity to nicotine withdrawal.
The rewarding effects of nicotine are mediated via enhanced dopaminergic mechanisms:
Research has shown that the rewarding effects of nicotine are mediated in large part via
enhanced dopamine neurotransmission in the mesolimbic pathway (Balfour, 2002; Corrigall,
1991; Mansvelder and McGehee, 2002; Watkins et al., 2000). This pathway originates in the
ventral tegmental area (VTA) and projects to various forebrain structures, including the nucleus
accumbens (NAcc) which plays a critical role in mediating the rewarding effects of many drugs
of abuse. For example, neurochemical studies have shown that nicotine administration produces
an increase in extracellular levels of dopamine in the NAcc from 50-100% above baseline values
(Ferrari et al., 2002; Fu et al., 2000; Di Chiara and Imperato, 1988; Nisell et al., 1994). The close
relationship between NAcc dopamine release and nicotine reward has been demonstrated in
studies reporting that extracellular dopamine levels are enhanced in this region during nicotine
self-administration and following exposure to environmental cues that were repeatedly paired
with nicotine administration (Di Chiara, 2000; Lecca et al., 2006). These findings suggest that
enhanced dopamine neurotransmission in the NAcc plays an important role in mediating the
rewarding effects of nicotine.
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The negative effects of nicotine withdrawal involve reduced dopaminergic mechanisms in
adult rodents: Recent studies have demonstrated that the neurochemical effects of nicotine
withdrawal are opposite to the effects produced by administration of this drug. Specifically, adult
rats showing physical signs of nicotine withdrawal display a 20-35% decrease in extracellular
dopamine levels in the NAcc relative to baseline values (Carboni et al., 2000; Gaddnas et al.,
2002; Hildebrand et al., 1998, 1999; Rada et al., 2001). The latter studies also found that nicotine
withdrawal produces a decrease in extracellular levels of the dopamine metabolites 3,4dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the NAcc. These
metabolites provide an additional measure of dopamine neurotransmission because they are
breakdown products of dopamine via enzymatic degradation in the pre-synaptic terminal button
of the neuron. Some researchers have argued that there are limitations in the extracellular
sampling of dopamine via microdialysis techniques because of the high-affinity uptake of this
neurochemical by the dopamine transporter. Thus, metabolite measurements provide a useful
(albeit indirect) index of dopamine-related changes since they generally parallel the pattern of
changes observed with dopamine and are present at much higher concentrations than dopamine.
Primary thesis question: Do dopaminergic mechanisms mediate developmental
differences in nicotine withdrawal? The hypothesis that the neural mechanisms of nicotine
withdrawal involve decreased NAcc dopamine is consistent with studies showing reduced
extracellular levels of NAcc dopamine in rodents experiencing withdrawal from several drugs of
abuse including alcohol, opiates, and cocaine (Pothos et al., 1991; Rada et al., 2004; Weiss et al.,
1992). Thus, decreased NAcc dopamine is believed to be a common neurochemical marker of
withdrawal from drugs of abuse including nicotine. To our knowledge, however, changes in
NAcc dopamine have not been compared in adolescent and adult rats experiencing nicotine
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withdrawal. Thus, the goal of this study was to compare changes in extracellular levels of
dopamine in the NAcc of adolescent and adult rats experiencing nicotine withdrawal. We also
compared changes in extracellular levels of the dopamine metabolites DOPAC and HVA to
further assess the role of dopamine in mediating developmental differences in nicotine
withdrawal. In addition, this study also included a comparison of developmental differences in
NAcc levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA). Previous
neurochemical studies have demonstrated that adult rats experiencing nicotine withdrawal do not
display changes in 5-HIAA levels in the NAcc (Gaddnas et al., 2002; Hildebrand et al., 1998).
Thus, our measures of NAcc 5-HIAA served as a negative control condition whereby
neurochemical differences were not expected across our experimental conditions. Lastly, we
included measures of the physical signs of withdrawal during microdialysis testing to provide a
behavioral index of developmental sensitivity to nicotine withdrawal.
Secondary thesis question: Do inhibitory mechanisms contribute to developmental
differences in nicotine withdrawal? Research has shown that dopamine release in the NAcc is
inhibited by gamma-aminobutyric acid (GABA) neurotransmission in the dopamine cell body
region of the VTA. The inhibition of dopamine in the VTA occurs via a population of GABA
interneurons that form synapses onto VTA dopamine neurons that project to the NAcc (Johnson
and North, 1992; Kalivas, 1993; Mansvelder and McGehee, 2002; Mansvelder et al., 2002).
Microdialysis studies have shown that intra-VTA infusions of a GABAA receptor antagonist
produced an increase in extracellular dopamine levels in the NAcc (Ikemoto et al., 1997;
Westerink et al., 1996), whereas intra-VTA infusions of a GABAA agonist produced a decrease
in NAcc dopamine (Westerink et al., 1996). Although the inhibition of dopamine release via
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GABA systems has been well established, no one has compared the ability of GABAergic
systems in the VTA to inhibit dopamine release in the NAcc of adolescent and adult rats.
A developmental difference in the ability of VTA GABA to inhibit NAcc dopamine
might be expected based on previous studies showing that GABA systems are underdeveloped
during adolescence. For example, adolescent rats display lower levels of GABA, GABAconverting enzymes, and GABA receptors in the brain compared to adults (Coyle and Enna,
1976; Hedner et al., 1984). More recently, immunohistochemistry studies have demonstrated that
adolescent rats express lower levels of various GABAA receptor subtypes relative to adults
(Fritschy et al., 1994; Paysan et al., 1994; Yu et al., 2006). In addition, Fleming et al. (2007)
demonstrated that inhibitory currents in granule cells of the dentate gyrus are lower in adolescent
versus adult rats. Based on these findings, we suggest that GABA inhibition of the dopamine cell
bodies in the VTA is reduced during adolescence, and this provides a potential mechanism to
explain why adolescents might display reduced changes in NAcc dopamine during nicotine
withdrawal. To address this hypothesis, the present study compared developmental differences in
neurochemical changes of NAcc dopamine produced by intra-VTA administration of a GABAA
antagonist.
Background information regarding the use of in-vivo microdialysis to assess
extracellular levels of neurotransmitters: In-vivo microdialysis is a technique used in live
animals to extract samples of the extracellular environment in discrete brain regions to estimate
changes in neurotransmission. A probe consisting of a semi-permeable membrane tip is inserted
into the brain region of interest. A Ringer’s buffer medium known as artificial cerebral spinal
fluid (ACSF) is then delivered through the inlet of the probe at a constant rate by a syringe
pump, creating a concentration gradient across the microdialysis membrane. Molecules of a
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certain size enter the microdialysis probe via diffusion properties and the flow of ACSF
containing neurotransmitters (i.e., dialysate) is deposited into a collection vial through the outlet
of the probe. Reverse dialysis can also be used to deliver drugs into specific brain nuclei by
continuously perfusing the probe with ACSF that contains a given drug. The passage of
molecules across the membrane tip is determined by the concentration of neurotransmitter in the
area where the probe is implanted, the flow rate of the perfusate applied through the probe, and
the type of membrane used. The external diameter of the membrane is about 250-300 µm with
molecular weight cut-offs of 6,000-20,000 Daltons.
High performance liquid chromatography (HPLC) is used to separate components of a
sample (i.e., analytes) via reverse-phase ion-pairing retention on a chromatographic column. This
occurs via the use of a pump apparatus that circulates a mobile phase solution at high pressure to
deliver the sample through the separation column. The column consists of tightly packed silicon
beads containing alkyl-carbon chains (i.e., stationary phase) that interact with the analyte based
on its degree of hydrophobicity. Thus, the elution time of the analyte from the column depends
on its ability to interact with the stationary phase in the column. For example, the more
hydrophobic the analyte, the more it will interact with the column packing, and thus the more
time it will take to elute from the column. The elution time is also a function of the alkyl chain
length in the column packing, the mobile phase composition, and the flow rate applied to the
system. The time at which a specific analyte elutes is called retention time and is considered to
be a unique characteristic of the analyte.
HPLC is then coupled with electrochemical detection for quantification of the individual
analytes. The electrochemical detector consists of 2 electrodes that carry an electrical potential
which is set to oxidize in one electrode and reduce in the other as the separated analytes pass
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through the pre-set field potentials. Oxidation and reduction produced by the field potentials then
generate a measurable current that reflects the quantity of the analytes. The electrical current is
translated into a computerized image of the reaction in peak format, which can be quantified and
compared against a current that is generated from a standard containing a known concentration
of the neurotransmitter of interest. The area-under-the-curve or peak heights from a series of
standard injections are linearly related to the amount of analyte. Thus, a linear regression of these
standard injections is used to predict the amount of analyte in a sample containing an unknown
quantity.
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Methods
Animals: Male Wistar adolescent and adult rats (n=7-8 per group) were used.
Adolescents were between post-natal day (PND) 28-30 and adults were between PND 60-75 at
the time of the pump implantation surgery. All rats were handled for 5 days prior to the start of
experimentation and were given free access to food and water throughout the study. Rats were
housed in groups of 2-3 per cage in a humidity- and temperature-controlled (20-22oC) vivarium
using a 12-/12-hour light/dark cycle with lights on at 8:00 AM. The home cages consisted of a
rectangular Plexiglas® hanging cage (41.5 cm long x 17 cm wide x 21 cm high) with pine
bedding. The food and water were located above the animals’ living space on a wire platform
encased within a filtered top cover. Testing procedures were conducted during the light phase of
the rats’ light/dark cycle. The rats were bred in the Psychology Department from a stock of out
bred Wistar rats from Harlan, Inc (Indianapolis, IN). Rats were bred onsite to minimize stress in
adolescents that might have occurred if they had been shipped and tested close in time. All
procedures were approved by the University of Texas at El Paso Animal Care and Use
Committee and followed the guidelines of the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
Drugs: The drugs used in this experiment were (-) nicotine-hydrogen tartrate and
mecamylamine-hydrochloride purchased from Sigma Aldrich Inc. (St. Louis, MO), and
bicuculline-methochloride

purchased

from

Tocris

Biosciences,

Inc

(Ellisville,

MO).

Mecamylamine was dissolved in 0.9% sterile saline and injected via the intraperitoneal (IP) route
of administration in a volume of 1 ml/kg. Bicuculline was dissolved in artificial cerebrospinal
fluid (ACSF) and administered via reverse dialysis through the microdialysis probe that was in
the VTA.
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Surgical

preparation

of

osmotic

pumps:

Rats

were

anesthetized

with

an

isofluorane/oxygen mixture (1-3% isofluorane) prior to surgical preparation of 14-day Alzet
osmotic pumps purchased from Durect Corporation (model 2ML2; 1.0 µl/hour; Cupertino,
California) that were implanted subcutaneously on the back of the animal parallel to the spine.
Pumps were filled with nicotine (4.7 mg/kg/day for adolescents or 3.2 mg/kg/day for adults;
expressed as base). The concentration of nicotine in the pump was adjusted according to the
weight of the rat at the time of the surgery. The nicotine concentrations were based on previous
studies demonstrating that the infusion rate of nicotine was 1.5 times lower in adolescent versus
adult rats after 17 days of exposure to the same nicotine dose as used in the present study (see
Trauth et al., 2000). After surgery, the surgical incision was closed with 9-mm stainless steel
wound clips and treated with a topical antibiotic ointment.
Stereotaxic implantation of microdialysis probes: Thirteen days after the pump surgery,
rats were implanted unilaterally with 2 probes into the NAcc and the ipsilateral VTA. Rats were
implanted between PND 40-42 for adolescents and PND 72-87 for adults. The probes were
purchased from CMA-Microdialysis (model CMA 11; Solna, Sweden) with an active membrane
length of 2 mm in the NAcc and 1 mm in the VTA. The probes were perfused for at least 1 hour
prior to implantation at a rate of 0.5 µl/minute with ACSF composed of 145 mM NaCl, 2.8 mM
KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 5.4 mM d-glucose, and 0.25 mM ascorbic acid and adjusted
to a pH of 7.2-7.4. The probes were stereotaxically implanted into the brain regions using the
following coordinates for the NAcc from bregma [adolescent placements- anterior-posterior (AP)
= +2.2, medial-lateral (ML) = ±0.8, dorsal-ventral (DV) = -7.1; and adult placements- AP = +1.7,
ML = ±1.4, DV = -8.1] and the ipsilateral VTA [adolescent placement-AP = -4.0, ML = ±0.6,
DV = -7.4; and adult placements- AP = -4.8, ML = ±0.8, DV = -8.5]. Adolescent placements
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were derived from Philpot et al. (2001) and Pistis et al. (2004) and adult placements were derived
from O’Dell and Parsons (2004). The hemisphere that was implanted with the probe was
randomized across treatment groups to control for possible hemispheric differences across age
groups.
Following surgery, adolescent and adult animals were transferred to similar sized test
cages that consisted of a square Plexiglas® cage (24 cm long x 24 cm wide x 31 cm high) with
pine bedding. Food and water were available throughout dialysis testing. When comparing
adolescent and adult rats, some researchers are careful to adjust for the size of the cage since this
factor has been shown to influence exploratory behaviors such as sniffing, rearing, and
locomotor activity. This may be particularly important for studies assessing developmental
differences in affective measures such as anxiety-like behavior that are influenced by exploratory
behavior. However, previous work in our laboratory using different sized chambers has
consistently revealed that adolescent and adult rats tested in chambers of different sizes and
shapes (round versus square) display similar basal and somatic signs of withdrawal (O’Dell et
al., 2004 and 2006).
Microdialysis testing: The next day after probe implantation, the perfusate flow rate was
increased to 1.0 µl/minute for 1 hour to allow equilibration of the probes. Samples were then
collected in 10-minute intervals for 1 hour to establish a baseline period, and then for 3
additional 1-hour sampling periods following systemic administration of saline and 2 doses of
mecamylamine in increasing order (1.5 and 3.0 mg/kg, expressed as salt; IP). The doses of
mecamylamine were chosen based on previous studies demonstrating that they produce a place
aversion to environmental cues previously associated with withdrawal in nicotine-dependent rats
(O’Dell et al., 2007). In addition, reports from other laboratories have demonstrated that similar
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doses of mecamylamine produce decreases in extracellular levels of NAcc dopamine
(approximately 20-35% from baseline) in nicotine-dependent adult rats experiencing withdrawal
(Carboni et al., 2000; Gaadnas et al., 2002; Rada et al., 2001).
The last series of dialysate samples were collected during a 1-hour perfusion of
bicuculline-methochloride into the VTA probe (100 µM). This manipulation was done in order
to compare developmental differences in the ability of GABAA receptor blockade to produce
increases in extracellular levels of NAcc dopamine. All dialysate samples collected from the
NAcc were diluted with 10 µl of perchloric-acid (0.05 N) in order to preserve our samples and
prevent degradation of dopamine and the metabolites. After collection, the samples were
immediately frozen on dry ice and stored in a -70oC freezer until they were analyzed.
Assessment of the physical signs of nicotine withdrawal: Rats were monitored for somatic
signs of nicotine withdrawal for 10-minute observation periods following the administration of
saline and 2 doses of mecamylamine. The observed signs included blinks, writhes, body shakes,
teeth chatters, gasps, and ptosis. These measures of withdrawal have been widely used as a
reliable index of the physical signs of withdrawal in nicotine-dependent rats after systemic
administration of mecamylamine (Malin et al., 1994; O’Dell et al., 2004, 2006; Shram et al.,
2008). Animals were continuously observed for 10 minutes during which time the frequency of
any of the above signs displayed were recorded. Multiple successive counts of any sign required
a distinct pause between episodes. If present continuously, ptosis was counted only once. The
total number of somatic signs was defined as the sum of individual occurrences of the
aforementioned withdrawal signs during the entire 10-minute observation period.
Neurochemical analysis of dopamine, DOPAC, HVA and 5-HIAA: Dopamine and the
metabolites were quantified from a 10-µl sample injected into a HPLC system equipped with an
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ESA HR-80 80x4.6 mm column (3 µm BetaBasic packing material, C-18 stationary phase,
Chelmsford, MA) and eluted using a mobile phase composed of a 75 mM NaH2PO4
(monohydrate, monobasic) buffer (pH 3.75) with 10% acetonitrile, 0.025 mM sodium-EDTA,
0.4% (v/v) triethylamine and 1.7 mM 1-octanesulfonic acid sodium salt delivered at 1 ml/minute
by an ESA model 580 syringe pump (Chelmsford, MA). Quantification was achieved via an ESA
Coulochem II detector equipped with a coulometric sensor containing dual glassy carbon
working electrodes (Chelmsford, MA) set at +350 mV for the metabolites and -150 mV for
dopamine. The extracellular levels of dopamine and the metabolites were estimated using
external calibration curves with standards containing known concentrations of these
neurochemicals.
Histology: At the end of the experiment, all rats were deeply sedated with pentobarbital
(100 mg/kg, salt; IP) and perfused using 0.85% saline and then a 4% paraformaldehyde solution.
Following the perfusion, the brains were extracted and stored in formalin solution until they were
sectioned. Verification of the probe placements was achieved during tissue sectioning using the
Paxinos and Watson (1998) atlas. The probe placements were focused in the NAcc core region
for both adolescents and adults, as determined during sectioning of the brain tissue. The VTA
placements were all confined in this small brain region. As a final elimination criterion, each
animal’s baseline values had to fall within a range that was less than 2 standard deviations from
the group mean. Based on these criteria, n=3 adolescents and n=2 adults were excluded from the
study.
Statistical analyses: The physical signs of withdrawal were analyzed using repeatedmeasures ANOVA with age (adolescent and adult) as a between-subjects factor and drug
treatment (saline and mecamylamine) as a within-subject factor. Repeated-measures ANOVA
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was first conducted to examine whether there were age differences across the 6 baseline samples
of dopamine, DOPAC, HVA, and 5-HIAA. The data revealed that there were no age differences
in basal levels of dopamine or any of the metabolites. Our subsequent analyses were conducted
on values that were converted to % change from baseline [i.e., (dialysate value/average baseline
value) x 100%] in order to more clearly illustrate group differences across our experimental
conditions. The dialysate data as % change from baseline were then analyzed using repeatedmeasures ANOVA with age (adolescent and adult) as a between-subjects factor and time (10minute intervals) as a within-subject factor. Changes in neurotransmitter levels during the intraVTA bicuculline infusion were analyzed separately using repeated-measures ANOVA with age
(adolescent and adult) as a between-subjects factor and time (10-minute intervals during the 3
samples prior to and the 6 samples following intra-VTA bicuculline infusion) as a within-subject
factor. Wherever appropriate, significant interaction effects were further analyzed using Fisher’s
least significant difference tests with a modified Bonferroni correction factor for alpha inflation.
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Results
Total physical signs of withdrawal:
ithdrawal: Figure 1 illustrates the total physical signs of nicotine
withdrawal in adolescent and adult rats. In summary, the results revealed that mecamylamine
precipitated the physical signs of withdrawal to a greater extent in nicotine-dependent adult
versus adolescent rats. Our analyses revealed that baseline withdrawal signs were not different
between adolescent (5.8 ± 1.7) and adult (6.4 ± 2.4) rats [F (1, 12) = 0.2; ns]. A significant
interaction effect was observed between age and drug treatment [F (2, 22) = 4.3; P < 0.05].
Subsequent post-hoc
hoc analyses revealed that both age groups displayed an increase in the physical
signs of withdrawal relative to baseline, and th
this
is effect was larger in adult versus adolescent rats
(Ps < 0.05).
Individual signs of withdrawal:
ithdrawal: The table below illustrates the individual signs of
withdrawal. These behaviors are presented separately in order to examine whether the pattern of
developmental differences observed with the total signs is similar across individual behaviors.
Mean frequencies of individual withdrawal signs (± SE
SEM)
M) in adolescents
adolescent and adults
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In general, the pattern of enhanced signs of withdrawal in adults versus adolescents
ad
was
consistent between the total and individual signs of withdrawal. To further illustrate this point,
Figure 2 reflects gasping behavior which was the most frequen
frequentt and objective individual sign of
withdrawal. Our analysis of gasping reveal
revealed a significant drug treatment effect [F (1.3, 24) =
10.4; P < 0.05],, with mecamylamine producing an increase in gasping relative to baseline in both
groups. We also observed an age effect [F (1, 12) = 7.8; P < 0.05], and a subsequent post-hoc
post
analysis revealed that adult rat
rats displayed higher levels of gasping relative to adolescents
ad
following the highest dose of mecamylamine ((P < 0.05).
Baseline concentrations of NAcc dopamine and the metabolites: The table below reports
the raw (nM ± SEM) values of dopamine and the metabolites DOPAC, HVA and 5-HIAA
5
averaged across the 1-hour
hour baseline period. This was done to illustrate that there were no group
differences in baseline values in any of our neurochemical measures. Specifically, our
o analyses
of these data revealed that there were no age differences in our baseline measures of dopamine [F
[
(1, 14) = 0.3; ns],
], DOPAC [F (1, 12) = 0.2; ns], HVA [F (1, 12) = 1.4; ns], or 5--HIAA [F (1, 12)
= 0.1; ns].
Mean baseline concentrations
oncentrations of dopa
dopamine
mine and the metabolites (± SEM)

NAcc dopamine during nicotine withdrawal
withdrawal: Figure 3 illustrates % change in
extracellular levels of NAcc dopamine (± SEM) in adolescent and adult rats experiencing
nicotine withdrawal.. Overall, the results revealed that me
mecamylamine
camylamine produced a decrease in
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NAcc dopamine that was larger in nicotine-dependent adult versus adolescent rats. Our analyses
revealed a significant interaction between age and time [F (23, 322) = 2.0; P < 0.05], with both
age groups displaying a decrease in dopamine following mecamylamine administration that was
larger in adult versus adolescent rats. Specifically, adult rats displayed a larger decrease in NAcc
dopamine (average decrease of 44.1 ± 5.5% from baseline levels) versus adolescent rats (average
decrease of 20.1 ± 5.3% from baseline levels). Subsequent post-hoc analyses revealed that the
adult rats displayed a significant decrease relative to baseline at all time points following
mecamylamine except for the sample that was collected before administration of the highest dose
of mecamylamine (Ps < 0.05). In contrast, adolescents only displayed a significant decrease from
baseline during the 2nd-5th, 9th and 11th-12th time points after mecamylamine administration (Ps <
0.05). Post-hoc analyses examining age differences revealed that adults displayed larger
decreases in NAcc dopamine relative to adolescents at the 1st, 2nd, 7th and 12th time points after
mecamylamine administration (Ps < 0.05).
NAcc DOPAC during nicotine withdrawal: Figure 4 illustrates % change in extracellular
levels of NAcc DOPAC (± SEM) in adolescent and adult rats experiencing nicotine withdrawal.
Overall, the results revealed that mecamylamine produced a decrease in NAcc DOPAC that was
larger in nicotine-dependent adult versus adolescent rats. Our analyses revealed a significant
interaction between age and time [F (23, 276) = 1.6; P < 0.05], with adults displaying a decrease
in NAcc DOPAC following mecamylamine administration that was larger than the adolescent
rats. Specifically, adult rats displayed a decrease in NAcc DOPAC (average decrease of 20 ±
14.3% from baseline levels) that was not altered in adolescent rats. Post-hoc analyses revealed
that adult rats displayed a significant decrease relative to baseline during the final time point
after mecamylamine administration (P < 0.05). Also, the post-hoc analyses examining age
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differences revealed that adults displayed larger decreases in NAcc DOPAC relative to
adolescents during the 1st, 5th, and 12th time points after mecamylamine administration (Ps <
0.05). It should be noted that adults displayed an increase in NAcc DOPAC during the 3rd, 5th,
and 6th time points after saline administration (Ps < 0.05). However, adolescents did not display
this effect following saline administration.
NAcc HVA during nicotine withdrawal: Figure 5 illustrates % change in extracellular
levels of NAcc HVA (± SEM) in adolescent and adult rats experiencing nicotine withdrawal.
Overall, the results revealed that mecamylamine produced a decrease in NAcc HVA that was
larger in nicotine-dependent adult versus adolescent rats. Our analyses revealed a significant
interaction between age and time [F (23, 276) = 1.9; P < 0.05] with adults, but not adolescents
displaying a time-dependent decrease in NAcc HVA. Specifically, adult rats displayed a decrease
in NAcc HVA (average decrease of 21 ± 8.4% from baseline levels) that was not altered in
adolescent rats. Post-hoc analyses revealed that adults displayed a significant decrease relative to
baseline during the final 3 time points after administration of the highest mecamylamine dose (Ps
< 0.05). Also, post-hoc analyses examining age differences produced by mecamylamine

administration revealed that adults displayed a larger decrease in NAcc HVA relative to
adolescents during the last time point after administration of the highest mecamylamine dose (P
< 0.05). It should be noted that adults displayed an increase in NAcc HVA during the 5th and 6th

time points after saline administration (Ps < 0.05). However, adolescent rats did not display this
effect following saline administration.
NAcc 5-HIAA during nicotine withdrawal: Figure 6 illustrates % change in extracellular
levels of NAcc 5-HIAA (± SEM) in adolescent and adult rats experiencing nicotine withdrawal.
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Mecamylamine did not produce any changes in NAcc 5-HIAA in nicotine-dependent adolescent
or adult rats.
NAcc dopamine during intra-VTA administration of bicuculline: Figure 7 illustrates %
change in extracellular levels of NAcc dopamine during the 3 samples prior to and the 6 samples
following intra-VTA administration of bicuculline in adolescent and adult rats. Overall, the
results revealed that blockade of GABAA receptors in the VTA produced an increase in NAcc
dopamine of adult but not adolescent rats. There were no age differences in dopamine during the
3 samples prior to bicuculline administration across adolescent (2.2 ± 0.2 nM) versus adult (1.6 ±
0.2 nM) rats [F (1, 14) = 3.8; ns]. Our analyses revealed a significant interaction between age and
time [F (8, 88) = 17.9; P < 0.05], with adult rats displaying increases in NAcc dopamine that
were higher versus adolescents. Specifically, adults displayed a 2-fold increase in NAcc
dopamine following bicuculline infusion (i.e., from 56.0 ± 7.5% to 125.9 ± 10.7), whereas
adolescents only showed a slight increase (i.e., from 77.4 ± 5.5% to 87.9 ± 7.3%) in these
measures. Post-hoc analyses revealed that during the final 3 time points, adults displayed
significant increases in NAcc dopamine relative to the 3 samples prior to bicuculline (Ps < 0.05).
In contrast, adolescents only displayed a significant increase in NAcc dopamine in the final time
point relative to the 3 samples prior to bicuculline (P < 0.05). Also, post-hoc analyses examining
age differences revealed that adults displayed significantly higher NAcc dopamine relative to
adolescents during the final 3 time points after bicuculline (Ps < 0.05).
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Discussion
Summary: The major finding of this report is that the physical signs of nicotine
withdrawal and decreases in extracellular levels of dopamine in the NAcc were lower in
adolescent versus adult rats. The pattern of developmental differences in dopamine was also
consistent with the metabolites of this neurotransmitter, as decreases in extracellular levels of
DOPAC and HVA were also lower in the NAcc of adolescent versus adult rats. The present
report also demonstrated that intra-VTA administration of a GABAA antagonist produced an
increase in NAcc dopamine that was lower in adolescent versus adult rats. Thus, one possible
mechanism to explain reduced changes in NAcc dopamine during withdrawal in adolescent rats
is that inhibition of dopamine in the VTA is underdeveloped such that adolescents display less of
a decrease in NAcc dopamine during withdrawal.
Developmental differences in the behavioral effects of nicotine withdrawal: The present
study revealed that adolescents displayed fewer physical signs of nicotine withdrawal versus
adult rats. These findings are consistent with previous behavioral studies. For example, work in
our laboratory has demonstrated that adolescent rats display fewer physical signs of withdrawal
relative to adult rats across a range of nicotine doses to produce dependence and across a range
of mecamylamine doses to precipitate withdrawal (O’Dell et al., 2006). Moreover, recent work
has demonstrated that adolescent mice display fewer signs of nicotine withdrawal versus adults
under spontaneous withdrawal conditions (Kota et al., 2007). An examination of the individual
signs of withdrawal revealed a similar pattern of developmental differences relative to the total
physical signs of withdrawal. As an example, we observed that gasping behavior was
significantly higher during withdrawal in adults versus adolescents. This finding supports our
hypothesis that adolescent rats display less physical signs of withdrawal relative to adults.
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The pattern of results obtained with the physical signs of withdrawal is consistent with
studies comparing developmental differences in the negative affective properties of nicotine
withdrawal. Specifically, previous work in our laboratory and others has demonstrated that the
negative affective properties of nicotine withdrawal are also lower in adolescent versus adult rats
(O’Dell et al., 2007; Shram et al., 2008; Wilmouth and Spear, 2006) and mice (Kota et al., 2007).
For example, O’Dell et al. (2007) demonstrated that adolescent rats did not display aversion to
environmental cues repeatedly paired with nicotine withdrawal. Shram et al. (2008) also
demonstrated that adolescent rats display a lack of place aversion under both spontaneous and
precipitated withdrawal conditions. Kota et al. (2007) and Wilmouth and Spear (2006) utilized
the elevated plus maze to examine anxiety-like behavior in adolescents and adults experiencing
withdrawal. This procedure assesses how animals respond to an approach-avoidance situation
involving open elevated spaces that are avoided versus enclosed safe areas that are preferred.
The Kota and Wilmouth studies both reported that adult rodents experiencing nicotine
withdrawal displayed an increase in anxiety-like behavior, as measured by a decrease in openarm time relative to controls. However, this effect was not observed in adolescents. Taken
together, these studies suggest that adolescence is a period of development characterized by
reduced sensitivity to the negative affective properties of nicotine withdrawal.
Dopaminergic mechanisms appear to mediate developmental differences in nicotine
withdrawal: Our neurochemical results extend previous behavioral studies by providing a
potential mechanism for reduced sensitivity to nicotine withdrawal during adolescence. This
mechanism involves reduced dopamine neurotransmission in the NAcc, an effect that has been
well established in adult rats experiencing withdrawal from nicotine (Carboni et al., 2000;
Gaddnas et al., 2002; Hildebrand et al., 1998, 1999; Rada et al., 2001) and other drugs of abuse
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(Pothos et al., 1991; Rada et al., 2004; Weiss et al., 1992). The latter studies regarding nicotine
withdrawal have reported a 20-35% decrease in extracellular levels of NAcc dopamine during
nicotine withdrawal, and the magnitude of this effect is consistent with the 44% decrease in
NAcc dopamine observed in the present study. The major contribution of this report to the
literature; however, is that adolescent rats only displayed a 20% decrease in extracellular levels
of NAcc dopamine during nicotine withdrawal.
Consistent with the dopamine data, adolescent rats also displayed fewer changes in the
dopaminergic metabolites DOPAC and HVA relative to adults. The metabolite data are useful
for several reasons. First, they provide a supplementary (albeit, indirect) verification of the
changes we observed with dopamine neurotransmission since the metabolites generally produced
similar patterns of developmental differences during withdrawal. Second, they address an
inherent limitation in the sampling of dopamine via microdialysis procedures that underestimates
true concentrations of this neurotransmitter. This is because the high-affinity dopamine
transporter quickly transports dopamine out of the synaptic cleft and into the pre-synaptic
terminal button where it is metabolized into DOPAC and HVA. These inactive metabolites then
diffuse into the extracellular environment, allowing them to be sampled through the
microdialysis probe at higher concentrations relative to the retrieved levels of dopamine. Thus,
our metabolite data provided a verification of the developmental differences observed with
dopamine using a measure that produces a large signal. Third, the metabolite data allowed us to
detect differences that were not observed with dopamine, such as the increases in DOPAC and
HVA observed in adult rats following saline administration. The saline-induced increases in the
metabolites might reflect acute stress in the adult animal produced by a systemic injection. This
effect has also been observed in nicotine-dependent adult animals following intra-VTA
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administration of saline (Hildebrand et al., 1999). Fourth, the metabolite data suggest that our
developmental differences are specific to dopaminergic systems, since neither age group
displayed changes in extracellular levels of 5-HIAA during withdrawal. This is consistent with
previous studies showing that 5-HIAA is not altered in the NAcc of adult rats experiencing
nicotine withdrawal (Gaddnas et al., 2001; Hildebrand et al., 1998).
In this study mecamylamine was used as a pharmacological tool to compare
developmental differences in the neurochemical effects of withdrawal. Thus, our comparisons
focused on adolescent and adult rats that were exposed to nicotine and then given mecamylamine
to precipitate withdrawal. It may be argued that our observed changes in dopamine and its
metabolites reflect age-dependent differences in response to mecamylamine given in
combination with chronic nicotine treatment versus mecamylamine given alone. However, our
previous place conditioning studies revealed that adolescents chronically exposed to nicotine still
demonstrate less sensitivity to mecamylamine-precipitated withdrawal versus adults, even in
separate groups of adolescents that received a 2-fold higher dose of mecamylamine or 7
additional days of nicotine exposure (O’Dell et al., 2007). Furthermore, in the absence of
mecamylamine, the removal of a nicotine pump still produces less spontaneous signs of
withdrawal in adolescent versus adult rats (Shram et al., 2008) and mice (Kota et al., 2007).
It is also unlikely that developmental differences observed in this study can be attributed
to the effects of mecamylamine alone, since several reports have shown that this drug has little
behavioral or neurochemical effects in the absence of nicotine. For example, administration of
mecamylamine doses used in the present study do not alter the somatic signs of withdrawal or
produce place aversion in adolescent versus adult rats (O’Dell et al., 2007; Shram et al., 2008) or
mice (Kota et al., 2007). Also, separate laboratories have shown that mecamylamine alone does
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not alter extracellular levels of dopamine in the NAcc of adult rats (Carboni et al., 2000;
Gaddnas et al., 2002; Hildebrand and Svensson, 2000; Rada et al., 2001). Taken together, these
studies suggest that our results are not influenced by developmental differences in response to
mecamylamine. However, this potential limitation in the interpretation of the present findings
might be addressed in future empirical studies comparing developmental differences in nicotinic
receptor function.
It should be noted that adolescents display faster weight gain and metabolic rates of
nicotine than adults. Thus, it may also be suggested that the lack of withdrawal in adolescents is
due to lower levels of nicotine on the day of microdialysis testing relative to adults. However,
this potential confound was likely avoided because we implanted the adolescent rats with a pump
containing a 1.5 fold higher dose of nicotine as compared to adults. This adjustment factor was
based on a study showing that after 17 days of nicotine pump exposure, the infusion rates of
nicotine were 1.5 times lower in adolescent (3-4 mg/kg/day) versus adult rats (5 mg/kg/day;
Trauth et al., 2000). Thus, one might expect that adolescents receiving 1.5 times more nicotine
than adults would display equivalent nicotine levels as adults on the test day following 14 days
of nicotine exposure. Moreover, we have demonstrated that place aversion produced by nicotine
withdrawal is still lower in a group of adolescents that were tested after 21 days of nicotine
exposure during which time they received a new pump containing an adjusted nicotine dose 14
days after the initial pump implantation (O’Dell et al., 2007). Also, Kota et al., (2007)
demonstrated that adolescent mice given repeated systemic injections of nicotine that were
adjusted for weight still display less physical and affective signs of withdrawal as compared to
adults. Taken together, these studies suggest that the developmental differences observed in the
present study are not likely due to developmental differences in nicotine dosing or tolerance;
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however, future studies might directly assess this possibility at the ti
time
me point that was used in the
present study.
GABAergic inhibition of the dopaminergic mechanisms that mediate developmental
differences in nicotine withdrawal: The diagram below depicts our hypothesis regarding
developmental differences in nicotine withdrawal.

In adults, we hypothesized that administration of a GABA antagonist would increase
extracellular levels of NAcc dopamine. Our hypothesis was based on the finding that blockade of
GABAA receptors in the VTA of adult rats produces a 40-80% increase in extracellular levels of
NAcc dopamine, whereas stimulation of these receptors induces a 60% decrease in this measure
(see Ikemoto et al., 1997; Westerink et al., 1996). Indeed, the present findin
findings
gs are consistent with
previous reports showing that intra
intra-VTA infusions of bicuculline produced a 69% increase in
NAcc dopamine of adult rats.
The present study also explored the hypothesis that developmental di
differences
fferences in NAcc
dopamine during withdrawal are mediated via GABAergic inhibition of dopamine cell bodies in
the VTA. Our results demonstrated that blockade of GABAA receptors in the VTA did not alter
NAcc dopamine of adolescent rats as compared to adult rats that displayed a robust increase in
this measure. The finding that adolescents display
displayed reduced changes in NAcc dopamine
following intra-VTA bicuculline relative to adults is consistent with literature showing that
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GABA systems are underdeveloped during adolescence. For example, GABA-mediated
inhibition by postsynaptic GABAB receptors is not functional early in life, and GABA currents in
neonatal rat neurons are insensitive to benzodiazepine activation of GABAA receptors,
suggesting an immaturity in synaptic function during early development (Cherubini et al., 1991).
Moreover, adolescents display lower levels of GABA, GABA-converting enzymes, and GABA
receptors (Coyle and Enna, 1976; Hedner et al., 1984). Adolescents also express lower levels of
the α subunits of GABAA receptors compared to adult animals (Fritschy et al., 1994; Paysan et
al., 1994; Yu et al., 2006). Thus, the finding that blockade of GABA receptors in the VTA does
not alter NAcc dopamine in adolescent rats is likely due to underdeveloped inhibitory systems
that mediate VTA dopamine neurons and release dopamine into the NAcc. As a result, it is
possible that adolescent rats experiencing nicotine withdrawal display a lower magnitude of
decreases in NAcc dopamine as compared to adults because of a reduced ability of VTA GABA
to inhibit dopamine release in the cell body region. We recognize that our interpretation of these
data may be limited on the basis of pharmacological studies, and future studies will need to more
directly assess our hypothesis by comparing extracellular levels of VTA GABA in adolescent
and adult rats experiencing nicotine withdrawal.
Clinical implications of the present study: Our findings may have clinical relevance for
treating adolescent tobacco abuse. Specifically, the finding that adolescents display reduced
withdrawal suggests that treatments focusing on alleviating nicotine withdrawal may be less
effective in treating adolescent tobacco users. As an example, treatments that enhance dopamine
neurotransmission such as bupropion may be less effective in adolescent smokers that experience
fewer decreases in dopamine levels during withdrawal. There is clinical evidence to support this
suggestion since long-term abstinence rates do not appear to be closely associated with nicotine
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replacement therapies in adolescent smokers (Hanson et al., 2003: Hurt et al., 2000; Moolchan et
al., 2005). Also, nicotine replacement does not prevent the expression of nicotine withdrawal
symptoms in adolescent smokers (Killen et al., 2001). Moreover, a recent study that directly
compared adolescent smokers to non-smokers found that young smokers only exhibited mild
symptoms during withdrawal (anger and craving) that did not appear to be associated with selfreports of dependence or biological markers of cigarette use (Smith et al., 2008a). Another report
from this laboratory found that withdrawal symptoms on the quit day were not related to relapse
behavior in adolescent smokers (Smith et al., 2008b). These studies suggest that abstinence from
chronic tobacco use only produces mild withdrawal symptoms that are not related to continued
use or relapse behavior during adolescence. Thus, treatments focusing on alleviating withdrawal
may be less effective in adolescent tobacco abusers. Future studies are needed to determine
whether treatments that target nicotine withdrawal via enhanced dopamine neurotransmission are
equally effective in adolescent and adult smokers.
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Figure 1: Data reflect total somatic signs of withdrawal (±SEM) exhibited in a 10-minute
10
observation period during baseline and following mecamylamine administration in adolescent
and adult rats (n=7-8 per group
group).
). Asterisks (*) denote a significant difference from baseline
values (Ps < 0.05), and daggers (†) denote a significant difference between age groups (Ps
( <
0.05).

37

Figure 2: Data reflect the gasping behavior (±SEM) exhibited in a 10
10-minute
minute observation period
during baseline and following mecamylamine administration in adolescent and adult rats (n=7-8
(n=7
per group). Dagger (†) denotes a significant difference between age groups (P < 0.05).
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Figure 3: Data reflect % change in extracellular levels of NAcc dopamine (± SEM) plotted
across 10-minute
minute sample collections during baseline and following administration of saline and
then 2 doses of mecamylamine to precipitate withdrawal in adolescent and adult rats (n=7-8 per
group).. The average dopamine nM concentration (± SEM
SEM)) is noted below each treatment
condition collapsed across the 1 hour of sample collection. The arrows indicate the onset of drug
administration. Asterisks (*) denote significant differences from baseline levels (Ps
( < 0.05), and
daggers (†) denote significant
ant differences between age groups ((Ps < 0.05).
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Figure 4: Data reflect % change in extracellular levels of NAcc DOPAC (± SEM) plotted across
10-minute
minute sample collections during baseline and following administration of saline and then 2
doses of mecamylamine to precipitate withdrawal in adolescent and adult rats (n=7-8
(n=7 per group).
The average DOPAC nM concentration (± SEM) iis noted below each treatment condition
collapsed across the 1 hour of sample collection. The arrows indicate the onset of drug
administration. Asterisks (*) denote significant differences from baseline levels (Ps
( < 0.05), and
daggers (†) denote significant differences between age groups ((Ps < 0.05).
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Figure 5: Data reflect % change in extracellular levels of NAcc HVA (± SEM) plotted across
10-minute
minute sample collections during baseline and following administration of saline and then 2
doses of mecamylamine to precipitate withdrawal in adolescent and adult rats (n=7-8
(n=7 per group).
The average HVA nM concentration (± SEM) is noted below each treatment condition collapsed
across the 1 hour of sample collection. The arrows indicate the onset of drug administration.
Asterisks (*) denote significant differences from baseline levels ((Ps < 0.05), and daggers (†)
denote significant differences between age groups ((P < 0.05).
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Figure 6: Data reflect % change in extracellular levels of NAcc 55-HIAA (± SEM) plotted across
10-minute
minute sample collections during baseline and following administration of saline and then 2
doses of mecamylamine to precipitate withdrawal in adolescent and adult rats (n=7-8
(n=7 per group).
The average 5-HIAA
HIAA nM concentration (± SEM) is noted
ed below each treatment condition
collapsed across the 1 hour of sample collection. The arrows indicate the onset of drug
administration.
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Figure 7: Data reflect % change in extracellular levels of NAcc dopamine plotted across 1010
minute sample collections during the 3 samples prior to and the 6 samples following intra-VTA
intra
bicuculline administration in adolescent and adult rats (n=7
(n=7-8 per group).
). The average dopamine
nM concentration (± SEM) is noted below prior to and following bicuculline administration.
Asterisks (*) denote significant differences relative to the 3 samples collected prior to bicuculline
administration (Ps < 0.05), and daggers (†) denote significant differences between age groups
(Ps < 0.05).
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